Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07146191 · ClinicalTrials.gov registry record · Phase 1
RE104 Radiolabeled Mass Balance (hAME) Study
A Phase 1 study, sponsored by Reunion Neuroscience.
- Completed
- Registry status
- Phase 1
- Development phase
- 8
- Enrollment target
NCT07146191 is a Phase 1 study that has completed, run by Reunion Neuroscience. The registered enrollment target is 8 participants.
The verdict
NCT07146191, a Phase 1 study, has completed, sponsored by Reunion Neuroscience.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hours after SC dosing of \[14C\]-RE104.
Interventions
- DRUG 2-[14C]-RE104 for Injection
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2025-08-19 |
| Est. Completion | 2025-10-02 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07146191
The ClinicalTrials.gov registry entry for NCT07146191 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Reunion Neuroscience, which has 5 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 2-[14C]-RE104 for Injection is the first listed.
NCT07146191 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07146191 about?
NCT07146191 is a clinical study titled "RE104 Radiolabeled Mass Balance (hAME) Study". The purpose of this study is to characterize the absorption, metabolism and routes of excretion of RE104 and its metabolites in healthy volunteers. This study will quantify drug and metabolites in blood, urine, and feces samples collected before study drug administration and through at least 168 hou...
What is the current status of trial NCT07146191?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 8 participants. The study started on 2025-08-19. Estimated completion is 2025-10-02.
What interventions are being tested in trial NCT07146191?
The interventions under investigation include: 2-[14C]-RE104 for Injection (DRUG).
Who is sponsoring clinical trial NCT07146191?
This trial is sponsored by Reunion Neuroscience, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.